Full year report January-December 2015 Unless otherwise

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Full year report January-December 2015

Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. 2015 – a year of investments and growth. Zubsolv® revenue growth of 83 percent. Fourth quarter 2015 ▪      Total net revenues amounted to MSEK 228.3 (220.5). ▪      Zubsolv net revenue amounted to MSEK 120.3 (79.5). ▪      Earnings after tax were MSEK -51.8 (51.6). ▪      Earnings per share were SEK -1.50 (1.50). ▪      Cash flow from operating activities amounted to MSEK 6.3 (-7.3). ▪      Orexo received MGBP 5 milestone payment for Abstral® in Europe. ▪      Orexo recorded OX-MPI non-cash impairment charge of MSEK 62. ▪      Orexo announced new Abstral partner in the US. ▪      Orexo settled Abstral US patent litigation with Actavis. ▪      Orexo filed for FDA approval of new Zubsolv low dose. January-December 2015 ▪      Total net revenues amounted to MSEK 643.3 (570.3). ▪      Net revenues, adjusted 1), were MSEK 586.3 (396.7), up by 47.8 percent. ▪      Zubsolv net revenue amounted to MSEK 416.7 (228.0). ▪      Earnings after tax were MSEK -198.0 (-56.6). ▪      Earnings per share were SEK -5.74 (-1.73). ▪      EBITDA, adjusted 1), were MSEK -145.3 (-186.1), an improvement of MSEK 40.8. ▪      Cash flow from operating activities amounted to MSEK -102.2 (-487.3). ▪      Cash and cash equivalents amounted to MSEK 198.1 (284.5). ▪      Orexo broadened Zubsolv product range. ▪      FDA approved Zubsolv for induction treatment of opioid dependence. ▪      New clinical data established Zubsolv as effective, well tolerated for maintenance treatment of opioid dependence and increases patients’ work productivity. ▪      Zubsolv excluded from CVS Caremark preferred position effective from January 1, 2016 after closed tender process. ▪      New exclusive agreement with unnamed Pharmacy Benefit Manager in Managed Medicaid. ▪      Orexo divested the subsidiary Kibion. ▪      Orexo settled patent infringement litigation against Mylan regarding Edluar®. MSEK 2015 2014 2015 2014 Oct-Dec Oct-Dec Jan-Dec Jan-Dec Net revenues 228.3 220.5 643.3 570.3 Revenues from launched products 228.3 220.5 643.3 568.6 EBIT -44.3 59.0 -169.0 -25.0 EBITDA 24.8 64.1 -88.3 -12.5 Earnings after tax -51.8 51.6 -198.0 -56.6 Earnings per share before dilution, SEK -1.50 1.50 -5.74 -1.73 Cash flow from operating activities 6.3 -7.3 -102.2 -487.3 Cash and cash equivalents 198.1 284.5 198.1 284.5 Key figures adjusted for non-cash fixed Abstral® royalty 1) MSEK 2015 2014 2015 2014 Oct-Dec Oct-Dec Jan-Dec Jan-Dec Net revenues, adjusted 1) 228.3 186.0 586.3 396.7 EBITDA, adjusted 1) 24.8 29.6 -145.3 -186.1 1) The non-cash fixed Abstral royalty represents an amortization of fixed and unconditional payments received in connection with the 2012 agreement with ProStrakan. This was fully recognized in the P&L by May 2015. Teleconference CEO Nikolaj Sørensen and CFO Henrik Juuel will present the report at a teleconference on January 28, 2016 at 2:00 p.m. CET (08:00 a.m. EDT). Presentation slides are available via the link and on the website. Internet: http://financialhearings.nu/160128/orexo/ Telephone: 46 8 566 42652 (SE), +44 203 426 2845 (UK) or +1 347 329 1282 (US). For further information, please contact: Nikolaj Sørensen, CEO or Henrik Juuel, EVP and CFO Tel: +46 (0)18 780 88 00, E-mail: ir@orexo.com CEO’s comments The United States consume 80 percent of the world’s opioids, but only account for 4.6 percent of the world’s population and the amount of opioid painkillers prescribed is enough to medicate every single adult in the country for one month. The consequences, when opioids are abused, on the society is severe and in 2014, 28,647 people died from drug overdose with opioids[1] (http://connect.ne.cision.com#_ftn1) in the US. This a tripling since year 2000 and has created an outcry in major media in the US e.g. the cover page of the first Newsweek® of 2016 read “Why Are White Americans Dying Younger?”, with the answer being the prescription opioid epidemic. Since the initiation of our commercial journey for Zubsolv®, we have highlighted the significant unmet need for opioid dependence treatment. More than 10 million Americans are using opioids for non-medical purposes and less than 1 million receiving any type of treatment today. The need for actions from the authorities in the United States is imminent and this was one of the first topics raised by President Obama in his final State of the Union speech. We know several concrete improvements are being evaluated, one being how to double the amount of prescribers in this disease space (2). We have anticipated this type of change and it has been an integral part of our business plans since we decided to establish a commercial entity in the US. Two years into our commercial journey in the US, we finally see concrete steps in the right direction for the patients and for Orexo and this give me strong confidence in the journey have ahead of us. In a market facing dramatic changes, being at the forefront in terms of scientific documentation and developing a product range, providing the optimal convenience and flexibility for patients and physicians are important competitive differentiators. Thus, I am happy to report our registry study REZOLV is about to finalize the patient recruitment with more than 1,000 patients enrolled by the end of 2015. Also our product development has progressed and we launched two new tablet strengths in the fourth quarter. However, when I met physicians during the launch of these new tablets, they inquired about a tablet with lower strength to improve their ability to tapering down with Zubsolv. Thus, I am pleased to report that we have filed for approval a new lower dosage in Q4, 2015 and we anticipate FDA approval in Q4, 2016. While we continue to invest in the growth of Zubsolv, we also continuously assess where and how to optimize the use of our resources. As a reaction to the change in market access from January 1, 2016 we have made an adjustment in the sales force in selected geographies. This will increase efficiency and enable a focus where our presence has the highest return on investment potential. One such region is the State of New York where we won an exclusive regional contract to be implemented in March 2016. We will ensure we have sufficient resources in this region to optimize the value of this contract. Another important driver of the profitability of our commercial investments, is the price and I am pleased to report we have been able to increase the price of Zubsolv in January 2016. Our efforts to find a partner for Zubsolv outside the US and for our project OX -51 continue to progress well. We expect to finalize the full license agreement for Zubsolv outside the US in the first half of 2016. Like we have seen with Abstral® in Europe, the right partner for Zubsolv will further strengthening Orexo’s long term growth opportunities. Nikolaj Sørensen President and CEO 1 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm64...mm6450a3_w 2 Huffington Post, Oct 21, 2015. Please note Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Market Act. The information was provided for public release on January 28, 2016, at 8:00 a.m. CET. This report has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall prevail.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 258

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 145

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 60

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 39

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Alter Predictions for Texas Instruments Earnings Release

Updated Category News Views 48

Analysts Update Forecasts for Texas Instruments Earnings Texas Instruments Incorporated (NASDAQ: TXN) is set to unveil its third-quarter earnings results, scheduled for release after the market closes on a Tuesday evening. Investors are keenly anticipating the outcome as industry buzz suggests that earnings could reflect a notable change from previous figures. Current...

Continue Reading
Iris Energy Limited: Understanding Investor Rights and Legal Options

Updated Category News Views 117

Understanding Your Rights as an Investor in Iris Energy Limited As an investor in Iris Energy Limited, it’s essential to know your rights, especially during challenging times. The legal landscape surrounding securities can be complex, and having informed legal support is crucial. Many investors are unaware of their options and the potential to recover losses stemming...

Continue Reading
McKesson Corporation Set to Release Earnings This November

Updated Category News Views 108

McKesson Corporation's Second Quarter Earnings Announcement McKesson Corporation (NYSE: MCK) is preparing to release its earnings report for the second quarter of fiscal 2025, which will happen after the market closes. Investors and stakeholders can expect to see the detailed financial results made public on a Wednesday. This announcement is a significant moment for the...

Continue Reading
Advantech's Innovations at Medical AI Solutions Conference

Updated Category News Views 122

Advantech Unveils Cutting-Edge Medical AI Solutions Advantech, a renowned global leader in industrial IoT and edge computing solutions, is excited to announce its presence at the MedTech Conference, an event that gathers leading figures in healthcare technology to discuss innovations shaping the future of patient care. Attendees will find Advantech at Booth #1007,...

Continue Reading
Canada's Defence Investment Spurs Innovation and Growth for Draganfly

Updated Category News Views 236

Canada's Defence Investment: A New Era for Technological Advancement In a bold effort to enhance national security, the Canadian government has revealed a significant long-term defence investment package worth $80 billion. This strategic move, championed by Prime Minister Mark Carney, is designed to advance technological capabilities in defence, bolster domestic...

Continue Reading